Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2022.02.054 | DOI Listing |
Am J Cardiol
June 2022
The Physician Investor Newsletter, 115 Bingham Road, Columbia, MO, 65203-3577. Electronic address:
Commun Biol
November 2021
Serimmune, Inc., Goleta, CA, USA.
As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to spread, characterization of its antibody epitopes, emerging strains, related coronaviruses, and even the human proteome in naturally infected patients can guide the development of effective vaccines and therapies. Since traditional epitope identification tools are dependent upon pre-defined peptide sequences, they are not readily adaptable to diverse viral proteomes. The Serum Epitope Repertoire Analysis (SERA) platform leverages a high diversity random bacterial display library to identify proteome-independent epitope binding specificities which are then analyzed in the context of organisms of interest.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!